TIM
OXFD

Triodos Investment Management’s Oxford Immunotec Global PLC Ordinary Shares OXFD Stock Holding History

Triodos Investment Management’s Portfolio OXFD Stock Details OXFD Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2019
Q1 		– Sell
-100,000
Closed -$1.28M – 40
2018
Q4 		$1.28M Hold
100,000
– – 0.27% 40
2018
Q3 		$1.62M Hold
100,000
– – 0.28% 44
2018
Q2 		$1.29M Buy
+100,000
New +$1.35M 0.24% 48

Other funds holding OXFD

FLAM
First Light Asset Management Edina, Minnesota $1.12B AUM 114.45% 1-Year Est. Return
Invesco
Invesco Atlanta, Georgia $1.02T AUM 30.18% 1-Year Est. Return
CCM
Consonance Capital Management New York $7.28M AUM 43.59% 1-Year Est. Return
PC
Polar Capital London, United Kingdom $13.5B AUM 55.9% 1-Year Est. Return
RG
Redmile Group San Francisco, California $1.51B AUM 164.17% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
GIM
Granahan Investment Management Waltham, Massachusetts $2.07B AUM 56.45% 1-Year Est. Return
Alyeska Investment Group
Alyeska Investment Group Chicago, Illinois $35.4B AUM 33.54% 1-Year Est. Return
GPGA
Grandeur Peak Global Advisors Salt Lake City, Utah $427M AUM 39.14% 1-Year Est. Return
CAM
Cortina Asset Management Milwaukee, Wisconsin $1.62B AUM 15.44% 1-Year Est. Return

Triodos Investment Management's OXFD Position: Q1 2019 in Review

Triodos Investment Management sold out of Oxford Immunotec Global PLC Ordinary Shares (OXFD) in Q1 2019, closing a stake of 100,000 shares — an estimated $1.28M sold.

Triodos Investment Management first reported a position in OXFD in Q2 2018 and held it in 3 quarters. The position peaked at $1.62M in Q3 2018. 92 funds tracked by Wall St. Rank hold OXFD as of Q1 2019.

  • Triodos Investment Management reported no remaining Oxford Immunotec Global PLC Ordinary Shares position as of Q1 2019 after selling out during the quarter.
  • Triodos Investment Management sold 100,000 Oxford Immunotec Global PLC Ordinary Shares shares in Q1 2019, an estimated $1.28M.
  • Triodos Investment Management first reported a position in Oxford Immunotec Global PLC Ordinary Shares in Q2 2018 and held it in 3 quarters.
  • Triodos Investment Management's Oxford Immunotec Global PLC Ordinary Shares position peaked at $1.62M in Q3 2018.
  • 92 funds tracked by Wall St. Rank held Oxford Immunotec Global PLC Ordinary Shares as of Q1 2019.

Based on Triodos Investment Management's 13F filing for Q1 2019, filed 13 May 2019.